January 23, 2013
In the video below, Fool analysts David Williamson and Max Macaluso discuss drugmaker Dendreon (NASDAQ: DNDN ) as a possible takeover target in 2013.
While hope of a buyout has diminished as Dendreon's struggles mounted, the possibility still exists. However, there is one additional hurdle that might keep big pharma away from Dendreon, which investors are not talking about.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.